Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

MERUS LABS INTERNATIONAL INC T.MSL

"Merus Labs International Inc is a specialty pharmaceutical company. The Company acquires and licenses novel pharmaceutical products."


TSX:MSL - Post by User

Post by lscfaon Feb 14, 2017 8:33pm
357 Views
Post# 25846348

ebitda emphasis is sort changing the co.

ebitda emphasis is sort changing the co.ebitda does not give co. credit for low interest rate and low tax rate so market is mis-valuing the stock.


Current adj ebitda $10.85 mil
Annualized = $43.4 mil
EV/ ebitda multiple of 6 => $260.4 mil
Less net debt of $136.5 mil => equity of $124 mil
117 mil shs. => $1.06
 
Current adj. eps = $0.062
Annualized = $0.248
p/e multiple of 8 => $1.98

net loss   -6,317,410
fx losses (gains) 3,748,357
amort of intangibles 8,941,592
legal settlement 998,176
acquisition costs 0
derivative losses (gains) -77,410
adj net income 7,293,305
shs avg o/s 116,999,906
adj eps   $0.062


<< Previous
Bullboard Posts
Next >>